Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

David Venables joins Ark board

This article was originally published in Scrip

Executive Summary

Dr David Venables has joined Ark Therapeutics' board as executive director for manufacturing services. He will be responsible for building Ark's manufacturing services business which is key to the company's future development. Dr Venables joins from Intercell where he was responsible for building its manufacturing capabilities in Europe and the US, most recently as chief operating officer.

You may also be interested in...



Approval Beckons For Orchard’s Gene Therapy Libmeldy

Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.

Kite’s Tecartus PRIMEd For EU Market With CHMP Nod

Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.

Sobi’s Doptelet Disappoints In Large New Indication

A Phase III trial of Swedish Orphan Biovitrum’s Doptelet in solid tumor cancer patients with chemotherapy-induced thrombocytopenia has failed. The setback could affect the firm’s growth expectations. 

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel